HALO vs SYRE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
HALO Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Halozyme Therapeutics, Inc. (HALO) driven by superior Valuation, Growth & Margin while SYRE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, HALO trades at 9.5x Forward P/E with 56.7% operating margin (+39.2% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, HALO sits in CONSOLIDATION (26th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | HALO | SYRE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $11.5B | $9.8B | Larger Scale | HALO |
| Trailing P/E Ratio Valuation | 25.2x | N/M | Lower Multiple | HALO |
| Forward P/E Ratio Valuation | 9.5x | N/M | Lower Multiple | HALO |
| Revenue Growth (YoY) Growth | +39.2% | +0.0% | Higher Growth | HALO |
| Operating Margin (TTM) Profitability | 56.7% | 0.0% | Higher Margin | HALO |
| Net Profit Margin Profitability | 26.9% | 0.0% | Higher Margin | HALO |
| Return on Equity (ROE) Capital Efficiency | 216.4% | -35.0% | Higher ROE | HALO |
| 52-Week Range Position Momentum | 50% ($61โ$134) | 88% ($22โ$111) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 0.57ฮฒ ยท 59% Vol | 1.75ฮฒ ยท 59% Vol | Lower Realized Risk | SYRE |
| Unified Institutional Score Composite Signal | 59.9 / 100 (HOLD) | 44.4 / 100 (HOLD) | Higher Composite | HALO |